Results 21 to 30 of about 79,537 (233)
C-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Clinical Stage and Prognosis
The International Journal of Biological Markers, 2001 The aim of this study was to investigate the expression of the oncogene c-erbB-2 in gastric tumors. Immunohistochemical study of the expression of c-erbB-2 was performed in formalin-fixed, paraffin-embedded sections from 82 gastric adenocarcinomas using ...
C.T.F. Oshima +3 more
doaj +1 more source
C-erbB-2 Expression in Primary Breast Cancer
The International Journal of Biological Markers, 1999 c-erbB-2 is an oncoprotein which is overexpressed in up to 40% of primary breast cancers. c-erbB-2 overexpression is a bad prognostic factor in patients with lymph node-positive disease.
E. Tagliabue +3 more
doaj +1 more source
EGF and TGF-β1 effects on thyroid function [PDF]
, 2011 Normal epithelial thyroid cells in culture are inhibited by TGF-β1. Instead, transformed thyroid cell lines are frequently resistant to its growth inhibitory effect. Loss of TGF-β responsiveness could be due to a reduced expression of TGF-β receptors, as
Gabriella Mincione +7 more
core +2 more sources
The International Journal of Biological Markers, 1993 Selected murine monoclonal antibodies (MAb) have been shown to inhibit relevant tumor growth in vitro and in animal models. Recently, bispecific antibodies (BsMAb) have been developed which target cytolytic effector cells via one antibody binding site ...
I. Garcia De Palazzo +2 more
doaj +1 more source
Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer
Frontiers in Oncology, 2019 Despite the gradual decrease in incidence, gastric cancer is still the third leading cause of cancer death worldwide. Although chemotherapy enhances overall survival and quality of life in advanced disease, the median overall survival is < 12 months ...
Chiara Arienti +2 more
doaj +1 more source
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. [PDF]
, 2013 High expression of ERBB2 has been reported in medulloblastoma and ependymoma; EGFR is amplified and over-expressed in brainstem glioma suggesting these proteins as potential therapeutic targets. We conducted a molecular biology (MB) and phase II study to
Blaney, Susan M. +11 more
core +1 more source
The Journal of Cell Biology, 2002 c-erbB receptors are usually located in cell membranes and are activated by extracellular binding of EGF-like growth factors. Unexpectedly, using immunofluorescence we found high levels of c-erbB-3 within the nuclei of MTSV1-7 immortalized nonmalignant human mammary epithelial cells.
Martin Offterdinger +3 more
openaire +1 more source
Molecular Oncology, 2023 Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers. Attempts to develop targeted therapies still need to be established. Some oncogenic mechanisms in PDAC carcinogenesis harness the EGFR/ERBB receptor family. To explore the effects
Kathrin Hedegger +7 more
doaj +1 more source
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. [PDF]
, 2014 BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer.
Blackman, A +10 more
core +2 more sources
Sclerostin–erbB-3 interactions: Modulation of erbB-3 activity by sclerostin [PDF]
Biochemical and Biophysical Research Communications, 2010 To gain insights into the mechanism of action of sclerostin, a protein that regulates bone mass, we performed yeast two-hybrid analyses using human SOST (sclerostin) cDNA cloned into pGBKT7 DNA-binding domain vector as a bait, and a normalized, high-complexity, universal cDNA library in a GAL4 activating domain vector.
Theodore A, Craig, Rajiv, Kumar
openaire +2 more sources